Stipple Bio Raises $100 Million in Series A Financing for Precision Oncology Pipeline

The biotech company will use the funds to advance its lead candidate STP-100 into early clinical studies and expand its Pointillist Platform for developing targeted cancer therapies.

Apr. 6, 2026 at 11:38am

Got story updates? Submit your updates here. ›

Stipple Bio, a private biotechnology company focused on creating precision oncology therapies, has closed a $100 million oversubscribed Series A financing round. The funding will be used to progress the company's lead candidate STP-100, a novel Antibody Drug Conjugate (ADC), into early-stage clinical trials, as well as to further develop Stipple Bio's Pointillist Platform for identifying tumor-specific cell surface epitopes to enable the creation of targeted cancer treatments.

Why it matters

Stipple Bio's approach of targeting tumor-specific cell surface epitopes aims to improve the therapeutic index of cancer therapies and unlock previously intractable drug targets. This could lead to more effective and safer treatments for cancer patients. The significant Series A financing demonstrates investor confidence in the company's technology and pipeline.

The details

The Series A round was co-led by RA Capital, a16z Bio+Health, and Nextech Invest, with participation from existing investors Emerson Collective Investments, GV (Google Ventures), LoLa Capital Partners, and GordonMD Global Investments. The proceeds will fund Stipple Bio's operations into 2029, allowing the company to advance its lead candidate STP-100 into early clinical studies and further develop its Pointillist Platform for identifying additional tumor-specific targets.

  • Stipple Bio was founded in 2022 by cancer biology pioneers Dr. Aaron Ring and Dr. Aashish Manglik.
  • The Series A financing was closed in April 2026.
  • Stipple Bio expects to enter STP-100 into early-stage clinical trials in early 2027.

The players

Stipple Bio

A private biotechnology company harnessing epitope-level precision to create targeted cancer therapies.

Jeff Landau

Chief Executive Officer of Stipple Bio.

Dr. Vineeta Agarwala

General Partner at Andreessen Horowitz and lead investor for the a16z Bio+Health Fund.

Dr. Derek DiRocco

Partner at RA Capital Management.

Dr. Aaron Ring

Co-founder of Stipple Bio and Associate Professor, Translational Science and Therapeutics Division at Fred Hutch.

Dr. Aashish Manglik

Co-founder of Stipple Bio and Associate Professor, Pharmaceutical Chemistry at UCSF.

Got photos? Submit your photos here. ›

What they’re saying

“We are building upon deep cancer biology expertise to map, target and unlock tumor-specific epitopes which enable us to develop a pipeline of next-generation precision oncology therapeutics.”

— Jeff Landau, Chief Executive Officer of Stipple Bio

“Clinical experience with prior antibody drugs has taught us that epitope-level specificity matters. Since the earliest days of Stipple Bio, we've been impressed by the team's vision to move beyond tumor-specific gene expression and to pioneer tumor-specific 'epitomics' in precision oncology.”

— Dr. Vineeta Agarwala, General Partner at Andreessen Horowitz and lead investor for the a16z Bio+Health Fund

“Stipple Bio's Pointillist Platform introduces an epitope-level approach to targeting tumor biology that has the potential to meaningfully expand the set of druggable oncology targets. Lead candidate STP-100 illustrates how this strategy can drive precise tumor targeting while sparing normal tissues—a key step toward improving therapeutic index in ADCs.”

— Dr. Derek DiRocco, Partner at RA Capital Management

What’s next

Stipple Bio expects to enter its lead candidate STP-100, a novel Antibody Drug Conjugate (ADC), into early-stage clinical trials in early 2027.

The takeaway

Stipple Bio's innovative approach to targeting tumor-specific cell surface epitopes has attracted significant investor interest and funding, positioning the company to advance its lead candidate into clinical development and expand its precision oncology pipeline. This could lead to more effective and safer cancer treatments for patients.